Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients - PubMed
5 hours ago
- #exosomes
- #immunotherapy
- #multiple myeloma
- Pomalidomide boosts immune activity of dendritic cell-derived exosomes (DEXs) in multiple myeloma patients.
- Treatment increases DEX surface markers (CD80, CD86, HLA-DR) and enhances CD8+ T cell activation.
- Mechanistically, pomalidomide modulates MAPK and PI3K-Akt pathways, promoting T-cell metabolic reprogramming.
- Enhanced DEXs show increased pro-apoptotic effects on myeloma cells, suggesting potential as an antitumor vaccine.